Krystal Biotech, Inc. (KRYS)
300.88
+0.63
(+0.21%)
USD |
NASDAQ |
Nov 06, 16:00
299.88
-1.00
(-0.33%)
After-Hours: 20:00
Krystal Biotech Cash from Investing (Quarterly) : -57.98M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -57.98M |
| June 30, 2026 | -161.58M |
| March 31, 2026 | -63.58M |
| December 31, 2025 | 11.16M |
| September 30, 2025 | -4.286M |
| June 30, 2025 | -10.52M |
| March 31, 2025 | -54.77M |
| December 31, 2024 | -83.78M |
| September 30, 2024 | -34.33M |
| June 30, 2024 | -19.35M |
| March 31, 2024 | -25.98M |
| December 31, 2023 | -10.16M |
| September 30, 2023 | 105.19M |
| June 30, 2023 | -15.96M |
| March 31, 2023 | 3.563M |
| December 31, 2022 | -5.208M |
| September 30, 2022 | -14.74M |
| June 30, 2022 | -38.22M |
| March 31, 2022 | -55.91M |
| December 31, 2021 | -126.54M |
| September 30, 2021 | -37.17M |
| June 30, 2021 | -62.32M |
| Date | Value |
|---|---|
| March 31, 2021 | -0.747M |
| December 31, 2020 | -6.217M |
| September 30, 2020 | -2.709M |
| June 30, 2020 | -0.95M |
| March 31, 2020 | -1.305M |
| December 31, 2019 | -0.545M |
| September 30, 2019 | -0.705M |
| June 30, 2019 | -1.236M |
| March 31, 2019 | -2.482M |
| December 31, 2018 | -3.767M |
| September 30, 2018 | -2.755M |
| June 30, 2018 | -3.801M |
| March 31, 2018 | 0.00 |
| December 31, 2017 | -0.159M |
| September 30, 2017 | -0.012M |
| June 30, 2017 | -0.032M |
| March 31, 2017 | -0.007M |
| December 31, 2016 | -0.009M |
| September 30, 2016 | -0.001M |
| June 30, 2016 | -0.005M |
| March 31, 2016 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | -311.74M |
| Ionis Pharmaceuticals, Inc. | 23.50M |
| Ultragenyx Pharmaceutical, Inc. | 58.00M |
| BridgeBio Pharma, Inc. | 36.61M |
| Cytokinetics, Inc. | 67.93M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 91.25M |
| Cash from Financing (Quarterly) | 3.413M |
| Free Cash Flow | 310.08M |
| Free Cash Flow Per Share (Quarterly) | 2.927 |
| Free Cash Flow to Equity (Quarterly) | 90.52M |
| Free Cash Flow to Firm (Quarterly) | 90.25M |
| Free Cash Flow Yield | 3.37% |